Updated on July 15, 2020 to correct the following statement: “c. Why did the company agree to give a full refund, including for the 13,000 test kits that had been delivered, given that Aytu had a binding commitment to buy 500,000 test kits? Why is that in the interest of the company?” The refund is for the deposits paid for undelivered kits. The company is not required to give a refund for the 13... Source

By Mak Yuen Teen On July 14, 10.46 pm, Biolidics announced a five-year non-exclusive licensing agreement with Accelerate Technologies Pte Ltd (A*ccelerate), the commercialisation arm of A*STAR. The announcement said that the agreement was signed on Thursday, July 9. On Monday, July 13, 12.19 pm, a trading halt was called. Prior to the trading halt, the company’s share price had increased from 41... Source

By Mak Yuen Teen On April 26, I published an article called “Battling Disclosure Viruses” on this website where I discussed the placement of shares by Biolidics in March and its disclosures between March and April about its COVID-19 rapid antibody test kits. Coincidentally, later that same evening, the company published its responses to another set of SGX queries and its answers to questions posed... Source

Healthcare stocks (eg. hospital business, pharmaceutical companies, vaccine development, etc.) are having competitive advantages, therefore those with growing businesses are usually growth giant stocks. Between life and money, which is more important? The choice is clear (金钱诚可贵、生命价更高) to put life at a higher priority, therefore healthcare has been a high growth sector in most countries. Q&M Dental (SGX: QC7) is a young healthcare giant stock with focus in dental services. The company started business in year 1996, having main businesses in Singapore (79 branches), Malaysia and China.  For China, due to stronger competition and higher cost, subsidiary stock, Aoxin Q&M (SGX: 1D4) with poorer business there, is not a giant stock, not performing as go

By Mak Yuen Teen Starting from the end of March 2020, Catalist-listed Biolidics Limited made a series of announcements and press releases, and received extensive coverage in the local and international television and print media, regarding its “rapid test kits” for COVID-19. Its price and trading volume went off the charts. On the day of the first announcement and press release on 30 March at 5. Source